Indoco Remedies 관리

관리 기준 확인 3/4

Indoco Remedies CEO는 Sundeep Bambolkar, Feb2012 에 임명되었습니다 의 임기는 12.75 년입니다. 총 연간 보상은 ₹ 75.54M, 61.7% 로 구성됩니다. 61.7% 급여 및 38.3% 보너스(회사 주식 및 옵션 포함). 는 ₹ 53.26M 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 53.26M. 경영진과 이사회의 평균 재임 기간은 각각 7.9 년과 14 년입니다.

주요 정보

Sundeep Bambolkar

최고 경영자

₹75.5m

총 보상

CEO 급여 비율	61.7%
CEO 임기	12.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	7.9yrs
이사회 평균 재임 기간	14yrs

최근 관리 업데이트

Recent updates

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Is Indoco Remedies (NSE:INDOCO) A Risky Investment?

Dec 27

Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)

Dec 06

What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?

Nov 14

CEO 보상 분석

Sundeep Bambolkar 의 보수는 Indoco Remedies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	₹321m
Jun 30 2024	n/a	n/a	₹767m
Mar 31 2024	₹76m	₹47m	₹985m
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹65m	₹40m	₹1b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹46m	₹30m	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹28m	₹20m	₹930m
Dec 31 2020	n/a	n/a	₹734m
Sep 30 2020	n/a	n/a	₹571m
Jun 30 2020	n/a	n/a	₹393m
Mar 31 2020	₹18m	₹15m	₹241m
Dec 31 2019	n/a	n/a	₹302m
Sep 30 2019	n/a	n/a	₹264m
Jun 30 2019	n/a	n/a	₹111m
Mar 31 2019	₹15m	₹12m	-₹29m
Mar 31 2018	₹16m	₹12m	₹412m

보상 대 시장: Sundeep 의 총 보상 ($USD 895.98K )은 Indian 시장( $USD 264.36K ).

보상과 수익: Sundeep 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sundeep Bambolkar (64 yo)

12.8yrs

테뉴어

₹75,540,000

보상

Mr. Sundeep Vasant Bambolkar has been a Joint Managing Director at Indoco Remedies Limited since February 15, 2012. Mr. Bambolkar served as Chief Financial Officer at Indoco Remedies Limited from March 23,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Suresh Kare	Non-Executive Chairman & Whole time Director	61.3yrs	₹36.89m	4.7% ₹ 1.4b
Sundeep Bambolkar	Joint MD & Executive Director	12.8yrs	₹75.54m	0.18% ₹ 53.3m
Aditi Panandikar	MD & Executive Director	12.8yrs	₹85.42m	6.14% ₹ 1.8b
Pramod Ghorpade	Chief Financial Officer	3yrs	₹17.38m	데이터 없음
Ramanathan Hariharan	GM of Legal	1.9yrs	₹5.48m	데이터 없음
Kavita Inamdar	Chief Technical Officer	no data	₹7.57m	데이터 없음
Ajay Karajagi	President of Sales & Marketing	no data	데이터 없음	데이터 없음
Rajesh Usgaonker	Chief Marketing Officer	no data	데이터 없음	데이터 없음
Rajan Saawant	Vice President of Corporate HR	no data	데이터 없음	데이터 없음
Prashant Pathak	Head of OSD	no data	데이터 없음	데이터 없음
Abhilash Soral	Executive Vice President of International Business for Regulated Markets	no data	데이터 없음	데이터 없음
Hemant Joshi	Senior Vice President of Sales for API	no data	데이터 없음	데이터 없음

7.9yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 관리: INDOCO 의 관리팀은 노련하고 경험 (평균 재직 기간 7.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Suresh Kare	Non-Executive Chairman & Whole time Director	61.3yrs	₹36.89m	4.7% ₹ 1.4b
Sundeep Bambolkar	Joint MD & Executive Director	20.7yrs	₹75.54m	0.18% ₹ 53.3m
Aditi Panandikar	MD & Executive Director	20.7yrs	₹85.42m	6.14% ₹ 1.8b
Divakar Gavaskar	Independent Non-Executive Director	19.6yrs	₹580.00k	데이터 없음
Rajiv Kakodkar	Independent Non-Executive Director	17.6yrs	₹660.00k	0.013% ₹ 3.8m
Anand Nadkarni	Non-Executive Director	10.5yrs	₹360.00k	데이터 없음
Vasudha Kamat	Non-Executive & Independent Director	4.7yrs	₹500.00k	데이터 없음
Abhijit Gore	Independent Non-Executive Director	4.1yrs	₹460.00k	0.0054% ₹ 1.6m
Satish Shenoy	Independent Director	less than a year	데이터 없음	데이터 없음
Ajay Mulgaokar	Independent Director	less than a year	데이터 없음	데이터 없음

14.0yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: INDOCO 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 14 년).

Indoco Remedies 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

MD & Executive Director recently bought ₹4.6m worth of stock

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Recent updates

MD & Executive Director recently bought ₹4.6m worth of stock

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)